Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer (TREAT2)
Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98108
- VA Puget Sound
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- give voluntary signed informed consent
- have histologically documented prostate cancer
- have been on ADT treatment for 6 months prior to randomization or intermittent LHRHa for preceeding 12 months
- expected to continue LHRHa therapy uninterrupted for the next 12 months
- have total testosterone levels less than 50 ng/dL
- Have BMD of lumbar spine or femoral neck at or below the BMD thresholds
- have a Zubrod performance status <or equal to 1
- subject weight <300 lbs(<136 kg)
- agree to complete a daily diary of medication intake
- agree not to take excluded medications throughout the trial
- agree to use an effective method of contraception
- have adequate bone marrow, liver and renal functions
Exclusion Criteria:
- Currently or previously exposed
- within the past 5 years to intravenous bisphosphonates, strontium ranelate or Denosumab
- for more than 3 years to oral bisphosphonates
- within the last 45 days to PTH or PTH derivative, anabolic steroids or testosterone, SERMs, calcitonin, calcitriol or oral gluccorticoids
- have any disease or condition that would preclude an accurate evaluation of radiographs of the thoracic or lumbar spine
- have <8 evaluable vertebrae
- have a BMD T score <-4 at the lumbar spine or total hip or femoral neck
- have any history of other carcinomas within the last 5 years
- Serum PSA > 5ng/mL at baseline under ADT
- have Paget's disease, Cushing's disease, chronic hepatitis or cirrhosis or rheumatoid arthritis
- have active uncontrolled systemic viral, bacterial or fungal infections
- have a clinically significant concurrent illness or psychological, familial, sociological, geograhical or other condition that would not permit adequate follow-up and compliance
- received treatment with other investigational agents within 30 days
- taking finasteride, dutasteride, danazol or testosterone like substances
- taking herbal medicines or dietary supplements
- have a history of thromboembolic disease including DVT or pulmonary embolus
- have a QTcF of > or equal to 450 msec or congenital or acquired QTc prolongation
- have HIV
- calcicum urolithiasis prohibiting the use of vitamin D
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To confirm the efficacy of toremifene 80mg compared with placebo in the reduction in the risk of new bone fracture occurrences in men with prostate cancer on androgen deprivation therapy as measured by semiquantitative assessment of vertebral fractures
Time Frame: 36 months
|
36 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Wounds and Injuries
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Fractures, Bone
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Bone Density Conservation Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Toremifene
Other Study ID Numbers
Other Study ID Numbers
- G300213
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.